RPSA and melanoma: Various studies have observed that targeting LRP/LR for downregulation with LRP‐specific siRNA successfully inhibits numerous tumourigenic processes, as mentioned above, in several different cancer cell types including breast (MDA‐MB231 and MCF‐7) [16], cervical (HeLa) [17], neuroblastoma (IMR‐32), pancreatic (AsPC‐1) [18], oesophageal (WHC01) [16], melanoma (A375 and A375M) [19], and colorectal (SW‐480 and DLD‐1) [20].